ArticleMolecules (Basel, Switzerland)2020
Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Open access · goldAbstract read
In one paragraph
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1.Journal of medicinal chemistry · 2026Article
- Carbonic Anhydrase Inhibitors in Oncology.Sub-cellular biochemistry · 2026Review
- Development of heterocyclic derivatives as P-glycoprotein inhibitors against multidrug resistance: pharmacological activities, structure-activity relationship and target (2020-2024).RSC medicinal chemistry · 2025Review
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Review
- Dual Inhibitors of P-gp and Carbonic Anhydrase XII (hCA XII) against Tumor Multidrug Resistance with Piperazine Scaffold.Molecules (Basel, Switzerland) · 2024Article
- Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.Biologics : targets & therapy · 2024Review
- Discovery of benzochromene derivatives first example with dual cytotoxic activity against the resistant cancer cell MCF-7/ADR and inhibitory effect of theJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Isomers Recognition in HPLC-MS/MS Analysis of Human Plasma Samples by Using an Ion Trap Supported by a Linear Equations-Based Algorithm.International journal of molecular sciences · 2023Article
- Nano-gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer.IET nanobiotechnology · 2023Article
- Indoline-5-Sulfonamides: A Role of the Core in Inhibition of Cancer-Related Carbonic Anhydrases, Antiproliferative Activity and Circumventing of Multidrug Resistance.Pharmaceuticals (Basel, Switzerland) · 2022Article
- New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.Journal of medicinal chemistry · 2022Article
- Simultaneous Degradation Study of Isomers in Human Plasma by HPLC-MS/MS and Application of LEDA Algorithm for Their Characterization.International journal of molecular sciences · 2022Article
- The complex relationship between multiple drug resistance and the tumor pH gradient: a review.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.Journal of enzyme inhibition and medicinal chemistry · 2021Review
- Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?Molecules (Basel, Switzerland) · 2021Review
- Co-Delivery of Berberine Chloride and Tariquidar in Nanoliposomes Enhanced Intracellular Berberine Chloride in a Doxorubicin-Resistant K562 Cell Line Due to P-gp Overexpression.Pharmaceutics · 2021Article
- Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.ACS combinatorial science · 2020Review
- Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Elisabetta TeodoriDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.ORCID 0000-0002-9705-3875
Laura BraconiDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.ORCID 0000-0002-0861-0706
Silvia BuaDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.
Andrea LapucciDepartment of Health Sciences-Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy.
Gianluca BartolucciDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.ORCID 0000-0002-5631-8769
Dina ManettiDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.
Maria Novella RomanelliDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.ORCID 0000-0002-5685-3403
Silvia DeiDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.ORCID 0000-0003-0898-7148
Claudiu T SupuranDepartment of Neuroscience, Psychology, Drug Research and Child's Health-Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy.ORCID 0000-0003-4262-0323
Marcella CoronnelloDepartment of Health Sciences-Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy.
University of Florence · IT
Funding
Università degli Studi di Firenze Fondo Ricerca Ateneo RICATEN17Università degli Studi di Firenze Fondo Ricerca Ateneo RICATEN18
Abstract
A new series of
Indexed as
Antineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Biological TransportCarbonic Anhydrase InhibitorsCarbonic AnhydrasesDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmDrug StabilityHumansK562 CellsMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Carbonic Anhydrase InhibitorsCarbonic AnhydrasesDoxorubicinCA XII inhibitorsdual P-gp/CA XII inhibitory activityhybrid compoundsK562/DOXLoVo/DOXMDR reversersmultitarget ligandsP-gp modulatorsselective chemosensitizers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.